Navigation Links
Watson's Generic BONIVA® 150mg Receives FDA Approval
Date:3/20/2012

PARSIPPANY, N.J., March 20, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary Watson Laboratories, Inc. has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Ibandronate 150mg tablets, the generic equivalent to Roche's BONIVA® tablets. Watson intends to begin shipping the product in the second quarter. BONIVA® 150mg tablets had total U.S. sales of approximately $510 million for the twelve months ending January 31, 2012, according to IMS Health.  Ibandronate tablets are indicated to prevent and treat osteoporosis in women who have undergone menopause.  Roche has sued Watson for patent infringement in connection with Watson's ANDA for Ibandronate 150mg tablets.  That lawsuit remains pending.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affect
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Watsons Generic Yaz(R) Receives FDA Approval
2. K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus
3. Mylan Launches Generic Version of Percodan® Tablets
4. Mylan Launches Generic Version of Sandostatin®
5. Due to Generic Erosion, the Hypertension Drug Market Will Decline by $3 Billion from 2009 to 2019
6. Generic Drug Sector Gets Better Information on API Manufacturing Costs from Thomson Reuters and Rondaxe Enterprises
7. Thomson Reuters Explores the Opportunities and Challenges of Entering the Japanese Generic Drug Market
8. Hypertension Drug Market Will Experience Only Modest Annual Decline Through 2018, Despite Generic Erosion Of Many Branded Agents
9. Forty-two of Simceres Generic Drugs Enter Chinas Essential Drug List
10. GPhA Says BIO Cries Wolf on Senate Biogenerics Proposal
11. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Casodex(R) Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014 Research and Markets ... Biology Market 2014-2018" report to their offering. ... term synthetic biology covers the designing and engineering of ... as the redesigning of natural biological systems that provide ... a form of extreme genetic engineering because it not ...
(Date:7/28/2014)... NEW YORK , July 28, 2014 /PRNewswire/ ... for ConvergeHEALTH by Deloitte , has been ... Data Interchange Standards Consortium, a non-profit working to ... research data, particularly as it relates to electronic ... to continue CDISC,s mission of collaborating with organizations ...
(Date:7/28/2014)... July 28, 2014 Appistry, Inc. ... that bring the power of genomics to next-generation medicine, ... Appistry Pipeline Challenge . , Two Appistry staff ... the National Center for Genome Resources, and Mr. Neil ... Clinics of Kansas City. Rounding out the panel are ...
(Date:7/28/2014)...  InterMune, Inc. (NASDAQ: ITMN ) today ... financial results at the close of the U.S. markets ... webcast will be hosted by InterMune at 4:30 p.m. ... and others may participate in the conference call by ... replay of the webcast and teleconference will be available ...
Breaking Biology Technology:Global Synthetic Biology Market 2014-2018 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2InterMune to Release Second Quarter Financial Results on August 6 2
... 3, 2011 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ... March 31, 2011. The net income for the ... to a net loss of $14.1 million during the same ... March 31, 2011 was related primarily to the $34.2 million ...
... May 2, 2011 Anadys Pharmaceuticals, Inc. (Nasdaq: ... 2011 financial results on Thursday, May 5, 2011, after the ... conference call and webcast on Thursday, May 5, 2011 at ... 2011 financial results and highlights and to provide an update ...
... WAGENINGEN, Netherlands, May 2, 2011 Dyadic International, ... company focused on the discovery, development, manufacture and ... biopharmaceutical, biofuels and industrial enzyme industries, announced today ... B.V. ("Dyadic Netherlands"), has entered into a research ...
Cached Biology Technology:MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 2MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 3MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 4MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 5Anadys Pharmaceuticals to Report First Quarter 2011 Financial Results 2Dyadic Netherlands Enters Into R&D Collaboration With Sanofi Pasteur and EnGen Bio 2
(Date:7/29/2014)... news for parents of preterm babies latest research from ... time they become teenagers, the brains of many preterm children ... , A study conducted by the University,s Robinson Research ... child experiences no brain injury in early life, their cognitive ... their term-born peers. , However, the results of the study, ...
(Date:7/28/2014)... drugs already approved by the U.S. Food and Drug ... growth of certain bacterial pathogens inside human cells, including ... fever. The findings, published in mBio , the ... demonstrate a new way of identifying non-antibiotic drugs that ... A handful of drugs on the list inhibit the ...
(Date:7/28/2014)... TEMPE, Ariz. - Reactions among minerals and organic compounds ... deep carbon cycle, they provide energy for the deep ... life. However, very little is known about how minerals ... Arizona State University have demonstrated how a common mineral ... negating the need for toxic solvents or expensive ...
Breaking Biology News(10 mins):Preterm children's brains can catch up years later 2New route to identify drugs that can fight bacterial infections 2Mineral magic? Common mineral capable of making and breaking bonds 2Mineral magic? Common mineral capable of making and breaking bonds 3
... Springer will publish The HUGO Journal in cooperation ... Springer as Genomic Medicine, The HUGO Journal has ... Members of HUGO will receive free access to the ... discounted rates. The HUGO Journal will focus ...
... announced today that its Ewell Sale Stewart Library has ... Heritage Library. The BHL is a group of 12 ... worldwide dedicated to digitizing the published literature on biodiversity ... more widely available. Scanning and cataloguing the materials preserves ...
... New evidence for ice-free summers with intermittent winter sea ... a period of greenhouse conditions - gives a glimpse of ... warming. Records of past environmental change in the Arctic ... period between 100 and 65 million years ago leading up ...
Cached Biology News:Academy Library accepted to prestigious Biodiversity Heritage Library 2Arctic climate under greenhouse conditions in the Late Cretaceous 2Arctic climate under greenhouse conditions in the Late Cretaceous 3
... serum biomarker chip to profile the relative ... chip containing 120 human cancer serum biomarker-specific ... discovery scientists to study panels of biomarkers ... and the likelihood of recurrence of cancer. ...
... is a highly sensitive reagent for the ... a purified form of recombinant E. coli ... which is sensitive to changes in its ... Phosphate Sensor is rapid and tight (Kd ...
... fume hood ventilates and purifies ... release of exhaust. Bonded charcoal ... Configurations are available with vertical ... final HEPA filter, work bench ...
Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation,of endotoxins for research purposes....
Biology Products: